pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 15·1 min read
save

Study reveals how Epstein-Barr virus triggers immune response in multiple sclerosis

Jul 15, 2026·read at STAT ↗Positive

A study published in Science Translational Medicine describes how infection with Epstein-Barr virus (EBV) initiates the immune reactions that lead to inflammation and nerve damage in people with multiple sclerosis (MS). The researchers mapped the viral mechanisms that appear to drive the disease process.

Lead author Kjetil Bjornevik said that understanding these mechanisms opens the door to developing EBV‑targeted vaccines or antiviral drugs that could prevent or manage MS symptoms without the heavy side effects of current immunosuppressants.

Syed Rizvi, director of the Multiple Sclerosis Center of Rhode Island, who was not involved in the work, noted that the findings push MS research toward more precise therapeutic approaches.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: New study untangles how Epstein-Barr viral infection triggers immune response in multiple sclerosis”

read at STAT ↗
492 words · retrieved Jul 15
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
BARR5Ultragenyx Pharmaceutical Inc.2
drugs
Rare Disease2
topics
Multiple Sclerosis7Immunology5Infectious Disease3Rare Disease2Vaccines2Diagnostics CompanyVaccine

related stories

  • 3d agoGSK laying off 1.2K+ in BelgiumBioSpace
  • 5d agoBioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survivalBioSpace
  • Sep 14After a brief storm of political headwinds, mRNA is back with strong momentumBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Jun 18Moderna flu vaccine wins unanimous support from FDA panelBioPharma Dive